Sumitomo Mitsui Trust Group Inc. Sells 205,564 Shares of CRISPR Therapeutics AG $CRSP

Key Points

• Sumitomo Mitsui Trust Group cut its stake in CRISPR by 9.5%, selling 205,564 shares in Q4 and now holds about 1,958,111 shares (~2.05%) valued at $102.7M.
• CRISPR reported a quarterly EPS loss of -$1.37 (missing estimates by $0.22) with revenue plunging 97.8% to $0.86M; the stock has a $5.26B market cap and a one‑year range of $33.03–$78.48.
• Analyst sentiment is mixed — consensus is a Moderate Buy with a $64.53 target (individual targets range $33–$110) — and insiders have sold ~141,828 shares in the past 90 days, including CEO Samarth Kulkarni's 60,000‑share sale.

Sumitomo Mitsui Trust Group Inc. decreased its holdings in CRISPR Therapeutics AG (NASDAQ:CRSP - Free Report) by 9.5% during the fourth quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The firm owned 1,958,111 shares of the company's stock after selling 205,564 shares during the period. Sumitomo Mitsui Trust Group Inc. owned about 2.05% of CRISPR Therapeutics worth $102,683,000 as of its most recent filing with the Securities & Exchange Commission.

A number of other hedge funds and other institutional investors have also bought and sold shares of CRSP. Orbis Allan Gray Ltd increased its stake in CRISPR Therapeutics by 76.9% in the second quarter. Orbis Allan Gray Ltd now owns 2,764,532 shares of the company's stock worth $134,467,000 after purchasing an additional 1,201,600 shares during the period. SR One Capital Management LP increased its stake in CRISPR Therapeutics by 94.4% in the third quarter. SR One Capital Management LP now owns 2,038,763 shares of the company's stock worth $132,132,000 after purchasing an additional 989,812 shares during the period. State Street Corp increased its stake in CRISPR Therapeutics by 35.6% in the second quarter. State Street Corp now owns 3,270,596 shares of the company's stock worth $159,082,000 after purchasing an additional 859,334 shares during the period. JPMorgan Chase & Co. increased its stake in CRISPR Therapeutics by 98.3% in the third quarter. JPMorgan Chase & Co. now owns 593,416 shares of the company's stock worth $38,459,000 after purchasing an additional 294,222 shares during the period. Finally, O Neil Global Advisors Inc. purchased a new stake in CRISPR Therapeutics in the third quarter worth $10,934,000. Hedge funds and other institutional investors own 69.20% of the company's stock.

CRISPR Therapeutics Stock Performance

CRSP stock opened at $54.83 on Tuesday. The firm has a market cap of $5.26 billion, a price-to-earnings ratio of -8.41 and a beta of 1.80. The firm has a 50-day simple moving average of $51.49 and a two-hundred day simple moving average of $56.10. CRISPR Therapeutics AG has a one year low of $33.03 and a one year high of $78.48.

CRISPR Therapeutics (NASDAQ:CRSP - Get Free Report) last issued its quarterly earnings results on Friday, February 13th. The company reported ($1.37) earnings per share for the quarter, missing the consensus estimate of ($1.15) by ($0.22). CRISPR Therapeutics had a negative return on equity of 26.31% and a negative net margin of 16,569.77%.The business had revenue of $0.86 million during the quarter, compared to analyst estimates of $4.72 million. During the same period in the prior year, the business posted ($1.01) EPS. CRISPR Therapeutics's revenue was down 97.8% compared to the same quarter last year. As a group, equities analysts predict that CRISPR Therapeutics AG will post -5.16 earnings per share for the current fiscal year.

Analysts Set New Price Targets

CRSP has been the topic of a number of recent analyst reports. Citizens Jmp reduced their target price on CRISPR Therapeutics from $86.00 to $80.00 and set a "market outperform" rating on the stock in a research note on Friday, January 30th. Morgan Stanley reiterated an "underweight" rating and issued a $33.00 target price on shares of CRISPR Therapeutics in a research note on Tuesday, February 17th. Truist Financial upgraded CRISPR Therapeutics to a "strong-buy" rating in a research note on Wednesday, March 25th. Piper Sandler reiterated an "overweight" rating and issued a $110.00 target price (up from $105.00) on shares of CRISPR Therapeutics in a research note on Tuesday, March 17th. Finally, Weiss Ratings restated a "sell (d-)" rating on shares of CRISPR Therapeutics in a research note on Wednesday, January 21st. One research analyst has rated the stock with a Strong Buy rating, ten have issued a Buy rating, six have given a Hold rating and two have given a Sell rating to the company's stock. According to data from MarketBeat, the stock presently has a consensus rating of "Moderate Buy" and a consensus target price of $64.53.

Insider Buying and Selling at CRISPR Therapeutics

In other news, CEO Samarth Kulkarni sold 60,000 shares of the business's stock in a transaction that occurred on Thursday, January 22nd. The stock was sold at an average price of $60.23, for a total value of $3,613,800.00. Following the completion of the sale, the chief executive officer directly owned 134,201 shares in the company, valued at $8,082,926.23. The trade was a 30.90% decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this link. Also, insider Naimish Patel sold 3,150 shares of the company's stock in a transaction on Monday, March 16th. The shares were sold at an average price of $48.26, for a total value of $152,019.00. Following the completion of the sale, the insider owned 13,143 shares of the company's stock, valued at approximately $634,281.18. The trade was a 19.33% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. Over the last ninety days, insiders sold 141,828 shares of company stock valued at $7,744,397. 4.30% of the stock is owned by company insiders.

CRISPR Therapeutics Profile

CRISPR Therapeutics AG is a biopharmaceutical company specializing in the development of gene-editing therapies based on the CRISPR/Cas9 platform. The company applies its proprietary technology to modify genes in human cells, aiming to create durable treatments for a range of serious diseases. Its research and development efforts focus on both ex vivo and in vivo applications, enabling targeted correction or disruption of disease-causing genes.

Among its lead programs is CTX001, an ex vivo edited cell therapy designed to treat sickle cell disease and transfusion-dependent β-thalassemia in collaboration with Vertex Pharmaceuticals.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.